Biosimilars: Getting the flock to market – PMLiVE

[ad_1] Biosimilars have now been with us for over 10 years. In case you haven’t been paying attention for the past decade, a biosimilar is a highly similar version of an originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost.   Biosimilars don’t offer the…

What’s harder than making copycat biotech drugs? Selling them – Pharmacy Today, American Pharmacists Association, pharmacist.com

[ad_1] Biosimilars—copycat versions of expensive biotechnology drugs—would seem a viable response to patient and provider outcry over steep medication costs, yet efforts to bring them to market have struggled. Not only do makers of biosimilars have to contend with user and doctor loyalty to existing drugs that have been effective,…

Biocon’s biosimilars withdrawn in EU – pharmaphorum

[ad_1] Shares in Biocon have fallen after the company withdrew two filings for biosimilars in Europe because of ongoing concerns over its manufacturing facility. The company said the withdrawal of its Herceptin (trastuzumab) and Neulasta (pegfilgrastim) biosimilars were regulatory requirements after EU authorities wanted to re-inspect manufacturing facilities in Bangalore….